Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$19.00Cboe Real-Time Last Sale as of 2:19PM ET 7/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.22(1.17%)
Bid (Size)$18.98 (100)
Ask (Size)$19.00 (461)
Day Low / High$18.69 - 19.04
Volume316.0 K

Analyst Actions: Credit Suisse Cuts Aimmune Therapeutics PT to $30 from $36, Assumes Coverage at Outperform on Peanut Allergy Drug - Stock Up 3%

2:04PM ET 5/21/2019 MT Newswires
Credit Suisse has cut its price target on Aimmune Therapeutics (AIMT) to $30 from $36 while assuming its outperform rating, betting on its current leadership in the peanut allergy treatment space with its late-state asset AR101 and its being a possible takeover target. The company has no commercial business income currently.

"Beginning next year, we expect AR101 to generate revenue for the company with unadjusted potential sales of $1.2B by 2024, vs. no product revenues currently," Credit Suisse said in a note.

"From an M&A perspective, we believe that Aimmune is an acquisition target from a position of strength, as it has an asset that is likely to be approved near-term," the analyst said. "A company could acquire prior to approval and shape the commercial trajectory of the asset."

Price: 20.24, Change: +0.59, Percent Change: +3.00